BIGBEAR Pharmaceutical announces the approval of Letermovir and Olaparib in Laos

Vientiane, Laos - September 20, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that 2 products have been approved by the Ministry of Health of Laos.

Approved drugs are:

Letermovir: sold under the brand name LETEDX.Letermovir is an antiviral drug for the treatment of cytomegalovirus infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections. 

  • Lao registered trade name: Lao Reg No.: 08L1172/24

Olaparib: Sold under the brand name OLADX. Olaparib is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.

  • Lao registered trade name: Lao Reg No.: 08L1169/24 

  • About BigBear Pharmaceuticals:

BigBear Pharmaceuticals is headquartered in Vientiane, the capital of Laos. The company is committed to drug research and development, production and sales, providing high-quality, safe and effective pharmaceutical products. BigBear Pharmaceuticals has established a good reputation in the Lao drug market with its excellent professional knowledge and innovation capabilities, and actively participates in international pharmaceutical cooperation and exchanges.

Forward-Looking Statements:

Within the scope of applicable laws and regulations, "plans," "goals," "expectations," "forecasts" and other similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that could differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulatory and/or economic conditions, uncertainties in clinical study results, exposure to various market risks and other factors beyond the Company's control.